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Abstract
Background: Study of in vivo antifungal activity of the hydroalcoholic extract (HE) and n-BuOH extract (BUTE) of
Sapindus saponaria against azole-susceptible and -resistant human vaginal Candida spp.
Methods: The in vitro antifungal activity of HE, BUTE, fluconazole (FLU), and itraconazole (ITRA) was determined by
the broth microdilution method. We obtained values of minimal inhibitory concentration (MIC) and minimum
fungicide concentration (MFC) for 46 strains of C. albicans and 10 of C. glabrata isolated from patients with
vulvovaginal candidiasis (VVC). VVC was induced in hyperestrogenic Wistar rats with azole-susceptible C. albicans
(SCA), azole-resistant C. albicans (RCA), and azole-resistant C. glabrata (RCG). The rats were treated intravaginally
with 0.1 mL of HE or BUTE at concentrations of 1%, 2.5% and 5%; 100 μg/mL of FLU (treatment positive control);
or distilled water (negative control) at 1, 24, and 48 h after induction of the infection, and the progress of VVC was
monitored by culturing and scanning electron microscopy (SEM). The toxicity was evaluated in cervical cells of the
HeLa cell line.
Results: The extracts showed in vitro inhibitory and fungicidal activity against all the isolates, and the MIC and MFC
values for the C. glabrata isolates were slightly higher. In vivo, the SCA, RCA, and RCG infections were eliminated by
21 days post-infection, with up to 5% HE and BUTE, comparable to the activity of FLU. No cytotoxic action was
observed for either extract.
Conclusions: Our results demonstrated that HE and BUTE from S. saponaria show inhibitory and fungicidal activity
in vitro, in addition to in vivo activity against azole-resistant vaginal isolates of C. glabrata and azole-susceptible and
resistant isolates of C. albicans. Also considering the lack of cytotoxicity and the low concentrations of the extracts
necessary to eliminate the infection in vivo, HE and BUTE show promise for continued studies with purified
antifungal substances in VVC yeast isolates.
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Background
Natural products have been traditionally used in the
control of various diseases, because they are a source of
many active compounds that show multiple therapeutic
effects, in addition to constituting models for the synth-
esis of a large number of pharmaceuticals [1]. The fruit
of Sapindus saponaria L. (Sapindaceae), a medium-sized
tropical tree found principally in America and India, has
shown antimicrobial activity [2-4], but few studies have
been carried out with this plant.
In a recent study, members of our research group iso-
lated and identified the principal constituents of the n-
BuOH extract (BUTE) of the pericarps of S. saponaria:
two acetylated triterpene saponins, S1 and S2, and also
an acyclic oligoglycoside. The same group also demon-
strated excellent inhibitory action in vitro of the water-
alcohol extract (HE) and BUTE against the yeasts Can-
dida albicans and non- C. albicans isolated from
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any medium, provided the original work is properly cited.patients with vulvovaginal candidiasis (VVC)[5], signal-
ing the possibility of using this plant as an antifungal
agent in this pathology. In spite of these recent investi-
gations of the constituents and biological properties of
S. saponaria,f e win vivo studies have yet been carried
out to establish a correlation with the in vitro results.
VVC is caused by abnormal growth of these yeast-like
fungi in the mucosa of the female genital system [6]. It
affects millions of women annually and can cause great
discomfort, affecting sexual and affective relations and
job performance, and is considered an important pro-
blem of world public health [7]. Management of patients
with VVC is often difficult because of the few available
therapeutic options; and furthermore, cross-resistance of
vaginal C. albicans has been detected to itraconazole
and fluconazole, which are the antifungal agents of
choice for treatment of this pathology [7,8]. In view of
the need for new therapeutic options for VVC and the
promising in vitro inhibitory activity of S. saponaria L.
against yeasts, we conducted a study of antifungal activ-
ity in vivo of HE and BUTE against azole-susceptible
and -resistant human vaginal Candida spp., and also of
the cell toxicity of these extracts.
Methods
Plant and components
Dry pericarps of the fruits of S. saponaria were collected
on the campus of the State University of Maringá,
Paraná, Brazil (UEM). The plant was identified by staff
members of the UEM Department of Botany, and an
exsiccate was deposited in the Herbarium of this institu-
tion (HUM 11710). The dried pericarps of the fruits
(450.0 g) of S. saponaria were ground and extracted
with EtOH:H2O (9:1) at room temperature, by a process
of dynamic maceration with constant mechanical stir-
ring. The extraction was carried out in an amber flask,
maintained at ambient temperature, for six consecutive
days, for 6 h per day. The extract was concentrated
under low pressure in a rotary evaporator, at a tempera-
ture of 40°C. After elimination of the solvent, the extract
was frozen in liquid nitrogen and lyophilized in a Martin
Christ Alpha 1-2 freeze dryer. The lyophilized extract
was stored in a closed plastic flask and kept frozen.
The HE of the pericarp (50.15 g) was chromato-
graphed in a column (ji = 4.0 cm) of silica gel 60
(Merck, Darmstadt, Germany), and eluted with solvents
of increasing polarity including hexane, dichloro-
methane, ethyl acetate, and methanol (Merck, Darm-
stadt, Germany). The solvents were evaporated at a
temperature of 40°C, frozen in liquid nitrogen, and lyo-
philized in a Martin Christ Alpha 1-2 freeze dryer. The
lyophilized dichloromethane, hexane, ethyl acetate, and
methanol fractions were stored in closed containers and
kept frozen. The methanol extract was suspended in
H2O and extracted with n-butanol, which after evapora-
t i o ng a v eas o l i dr e s i d u e( 2 8 . 9g )( B U T E ) ,w h i c hw a s
also lyophilized. The structures were established with
the use of spectroscopic methods (
1Ha n d
13CN M R ,
HSQC, HMBC, and ESI/MS) and by comparing them
with literature data [2,4].
Yeast isolates
For the experiments on in vitro susceptibility, 56 vaginal
isolates obtained from patients with VVC were tested,
including 46 isolates of C. albicans and 10 of C. glab-
rata, which are part of a bank of yeasts at the Medical
Mycology Laboratory/UEM. In this yeast bank, aliquots
of the yeasts are stored after their identification in 10%
glycerinated water at -20°C. The yeasts used in this
study were isolated and identified in 2008, by classical
methods [9-11] and also by rDNA sequencing [12].
Prior to each experiment, the isolates were reactivated
in Sabouraud Dextrose Broth (SDB) (Difco, Detroit,
USA) at 25°C for 24/48 h, seeded on Sabouraud Dex-
trose Agar (SDA) (Difco, Detroit, USA) with chloram-
phenicol (2.0 mg/mL), and incubated again under the
previous conditions. A new subculture was made in
CHROMágar Candida
® (Probac, France) to assure the
purity of the isolates.
Antifungal agents
Stock solutions of fluconazole (FLU) (5000 mg/mL; Pfi-
zer Inc., NY, USA) and itraconazole (ITRA) (1000 mg/
mL; Janssen Pharmaceutica, Titusville, NJ, USA) were
prepared. From the first prepared solution, new stock
solutions of FLU and ITRA were prepared at a concen-
tration of 10 times that of the final test concentration,
and diluted in bicarbonate-free RPMI-1640 with L-gluta-
mine, supplemented with 2% dextrose and buffered to
pH 7.0 with 0.165 M morpholinopropanesulfonic acid
(MOPS) (Sigma, Steinheim, Germany). The lyophilized
HE and BUTE extracts were dissolved in sterile distilled
water to obtain a 10 mg/mL solution of each extract.
Determination of minimum inhibitory (MIC) and
fungicidal concentrations (MFC)
The tests of susceptibility of Candida spp. to FLU and
ITRA were carried out according to the broth microdi-
lution method recommendedb yt h eC L S I( C l i n i c a l
Laboratory Standards Institute, 2002), and of susceptibil-
ity to HE and BUTE according to the same document,
with adaptations for natural products [13,14].
A suspension of yeast compatible with 1.0 to 5.0 × 10
6
colony-forming units per mL (CFU/mL) was prepared in
sterile saline, adjusting the cell density by means of a
spectrophotometer (Spectronic 70, Bausch & Lomb,
USA) at 530 nm with 90 ± 2% transmittance. From this
suspension, new dilutions were made: 1:50 in sterile
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many), thus obtaining the desired final inoculum of 0.5
to 2.5 × 10
3 CFU/mL. The tests were carried out in
sterilized plastic microplates (TPP Zellkultur Test Plate
96F, Switzerland) containing 96 wells arranged in 8
rows labeled A to H, each row with 12 wells numbered
1 to 12. Each row (A-H) corresponded to one isolate,
and each well received 100 μL of the measured inocu-
lum, except for the 12th well which was the negative
control. Aliquots of 100 μLo fR P M I( G i b c o ,N Y ,U S A )
were distributed from columns 2 to 11. Aliquots of
100 μL of FLU, ITRA, HE, or BUTE, prepared as pre-
viously described, were added to the columns of the
microplates, and from column 2 a 2-fold serial dilution
was made up to the 10th well (diluitions between
0.125 and 64.0 μg/mL for FLU, 0.03 and 16.0 μg/mL
for ITRA, and 9.0 and 5000.0 μg/mL for HE and
BUTE).
For each isolate tested, negative controls (only RPMI)
and positive (RPMI plus inoculum, with no antifungals
added) were included, for growth and for the possible
action of the diluent of the extracts or drugs (only buta-
nol, ethanol, or polyethyleneglycol 400 with the inocu-
lum). On each microplate a strain of Candida
parapsilosis (ATCC 22019) was included as the refer-
ence yeast. The plates thus set up were incubated in an
oven at 35°C with daily monitoring. After 48 h they
were read for FLU and ITRA in a microplate reader
(Asys Hitech GmbH, Eugendorf, Austria) and after 72 h
for the extracts, by visual comparison of the reflection
in a mirror.
The MIC for FLU/ITRA was determined as the lowest
concentration of the drug that was capable of inhibiting
50% of the growth of each yeast, with reference to its
respective positive control [13]. The criteria for defini-
tion of susceptibility/resistance to FLU/ITRA were those
established by CSLI [13]. For HE and BUTE, the MIC
was considered to be the smallest concentration of the
extract that was capable of inhibiting 100% of the inocu-
lum compared to its respective positive control [14].
The MIC50 and MIC90 for the drugs and extracts were
defined as the MICs capable of inhibiting 50% and 90%
of the isolates, respectively [13].
To determine the MFC, subcultures from all wells
showing growth inhibition were made by seeding 5.0 μL
in SDA at 25°C. After 48 h, the CFU were counted to
determine the viability. All the assays for determination
of the MIC and MFC were carried out in duplicate,
independently. The MFC for HE and BUTE was consid-
ered as the lowest concentration that impeded the
growth of 100% of the inoculum. The MFC50 and
MFC90 for the extracts were defined as the MFCs cap-
able of inhibiting 50% and 90% of the isolates,
respectively.
Experimental vaginal infection
A rat model was used as previously described [15], with
some adaptations. The experiments were carried out
with three yeast isolates, which were selected according
to the results of the in vitro tests: C. albicans susceptible
to FLU and ITRA (SCA), C. albicans resistant to ITRA
(RCA), and C. glabrata resistant to both antifungals
(RCG).
The experiments were carried out with groups of five
rats for each isolate, in duplicate and on two different
days. Non-oophorectomized Wistar rats (Rattus norvegi-
cus) weighing from 200 to 300 g and 70 days old (from
the UEM Central Animal Facility) were used. The rats
received subcutaneous injections of estradiol valerate
(Sigma, Steinheim, Germany) at a concentration of 0.2
mg/week/rat. Six days after the first injection of the hor-
mone, the animals were inoculated intravaginally with
10
8 yeast cells/mL of each isolate tested, prepared in 0.1
mL of sterile saline and counted in a Neubauer
chamber.
For the treatment, HE and BUTE were administered
intravaginally (0.1 mL at 1%, 2.5%, and 5.0% in distilled
water) at 1, 24, and 48 h after the induction of the vagi-
nal infection. Rats receiving FLU (3 doses of 100 μg
intravaginally over the same time periods as the
extracts) or distilled water served as positive and nega-
tive treatment controls, respectively. The kinetics of the
Candida vaginal infection in the treated and control rats
was monitored in each animal by means of the number
of CFU/mL in the vaginal fluid at 24 and 48 h after
induction of the infection, and on days 5, 7, 14, and 21.
The animal experimentation carried out in this investi-
gation was approved by the UEM Committee on Ethical
Conduct in Animal Use (Protocol No. 013/2006, Opi-
nion No. 050/2006).
Toxicity in cervical cells
Cells from the HeLa human cervical line were pre-
viously cultured in Eagle’s minimum essential medium
(MEM, PPA Laboratories, Germany) supplemented with
10% fetal bovine serum (FBS, Laborclin, Brazil), 0.1 mM
non-essential amino acids, and 1 mM sodium pyruvate,
at 37°C in a humid oven with 5% CO2. In the exponen-
tial growth stage, the cells were diluted in the same
medium and plated in volumes of 0.2 mL of a suspen-
sion of 2.5 × 10
5 cells per well in a 24-well plate (Corn-
ing Glass, New York, USA), and incubated in the same
conditions overnight to allow them to form a cell mono-
layer. The culture medium was replaced by serial dilu-
tions of the HE or BUTE extracts at 1%, 2.5%, 5%, and
10% concentrations, in triplicate. The control wells con-
tained only cells and culture medium. The microplate
was incubated again at 37 °C for 24 h, and the extracts
were replaced by a trypsin-EDTA solution to undo cell
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50% trypan blue. Live and dead cells in each well were
counted with the aid of light microscopy.
Scanning electron microscopy (SEM)
The vaginal epithelium of rats infected with CAS, CGR,
and CAR before and after treatment with HE and BUTE
was observed by SEM. After 48 h of infection and also
at the end of treatment, the rats to be analyzed by SEM
were killed with an overdose of anesthetics (Ketamine
and Xylazine, Parke-Davis Co, Morris Plains, NJ, USA).
The vagina was removed, washed, fixed in a solution of
2.5% glutaraldehyde in 0.1 M cacodylate buffer (Sigma
Chemical, St. Louis, MO, USA), and dehydrated in an
ascending ethanol series. The critical point was obtained
in a Balzers CPD-010 (Balzers Instruments, Balzers,
Liechtenstein) with carbonic gas. Metallization in gold
was carried out in a Balzers SCD-030 (Balzers Instru-
ments, Balzers, Liechtenstein). The vagina, uterine cer-
vix, and tissue sections of all rats were observed and
photographed with a JEOL-JSM 6360 LV scanning elec-
tron microscope (JEOL Ltd, Tokyo, Japan) at the Elec-
tron Microscopy Center, Federal University of Paraná/
Curitiba/Brazil.
Statistical analysis
The results were analyzed using Student’s t test and
Tukey’s test for multiple comparisons of the different in
vivo experimental treatment situations. The significance
level was set at 5%. The tests were carried out by means
of the program Graph Pad Prismâ version 3.0 (Graph
Pad Software Inc.).
Results
Plants and components
The presence of two acetylated triterpene saponins was
confirmed: saponin S1, hederagenin-3-O- (3,4-di-O-
acetyl-b-D-xylopyranosyl)- (1®3)-a-L-ramnopyranosyl-
(1®2)-a-L-arabinopyranoside; and saponin S2, hedera-
genin-3-O-(4-O-acetyl-b-D-xylopyranosyl)-(1®3)-a-L-
ramnopyranosyl-(1®2)-a-L-rabinopyranoside; and also
an acyclic oligoglycoside-1 (OGSA-1) in HE and BUTE,
as previously described [5].
Determination of in vitro minimum inhibitory and
fungicidal concentrations
T h em a j o r i t yo ft h eC. albicans isolates proved to be
susceptible in vitro to FLU and ITRA simultaneously (n
= 38) and a few were resistant to ITRA (n = 3), but
there was no resistance to FLU. Some of the C. glabrata
strains proved to be resistant to FLU (n = 2) and ITRA
(n = 4) and to both antifungals simultaneously (n = 2)
(Table 1). HE and BUTE in vitro inhibited all the yeast
isolates tested, including those that were susceptible-
dose dependent (SDD) to FLU and resistant to FLU
and/or ITRA. The values of MIC50 and MIC90 were
h i g h e rf o rF L U ,I T R A ,H E ,a n dB U T Ei nt h ei s o l a t e so f
C. glabrata. However, the variation of the MIC for HE
and BUTE was the same for C. albicans (9.0-≤5.0 × 10
3
μg/ml) and very similar for C. glabrata (75.0-≤5.0 × 10
3
μg/ml and 36.0-≤5.0 × 10
3 μg/ml, respectively) (Table 1).
Both extracts also exhibited fungicidal activity (MFC)
in vitro for all the yeasts tested, independently of
whether they were susceptible or resistant to azoles.
There was little variation among MFC50 and MFC90
(Table 1). The MFC values were similar to the range of
the MIC, confirming the important in vitro antifungal
activity.
Experimental vaginal infection
The results in vivo confirmed those in vitro,s i n c et h e
infection by SCA, RCA, and RCG was eliminated by 21
days post-infection, with a maximum concentration of
5% of HE and BUTE. In these experiments, the
untreated control rats remained infected until the end
Table 1 Anti-Candida activity in vitro of the
hydroalcoholic (HE) and butanolic (BUTE) extracts of
Sapindus saponaria in comparison to fluconazole (FLU)
and itraconazole (ITRA)
Drugs C. albicans (46)
b C. glabrata (10)
b
aMIC range FLU 0.125-32 (43)
c, (3)
d, (0)
e 2.0-64.0 (5)
c, (4)
d, (1)
e
ITRA 0.03-1.0 (38)
c, (5)
d, (3)
e 0.125-8 (3)
c, (3)
d, (4)
e
HE 9.0-≤5.0 × 10
3 36.0-≤5.0 × 10
3
BUTE 9.0-≤5.0 × 10
3 75.0-≤5.0 × 10
3
MIC50 FLU 0.25 8.0
ITRA 0.03 0.25
HE 9.0 36.0
BUTE 36.0 75.0
MIC90 FLU 16.0 64.0
ITRA 0.5 8.0
HE 310.0 620.0
BUTE 310.0 5.0 × 10
3
fMFC range HE 9.0-≤5.0 × 10
3 36.0-≤5.0 × 10
3
BUTE 9.0-≤5.0 × 10
3 75.0-≤5.0 × 10
3
MFC50 HE 310.0 2.5 × 10
3
BUTE 150.0 2.5 × 10
3
MFC90 HE 310.0 5.0 × 10
3
BUTE 310.0 5.0 × 10
3
a Minimum inhibitory concentration - MIC (μg/mL); MIC50 and MIC90 for drugs
and extracts: MIC capable of inhibiting 50% and 90% of the isolates,
respectively; In parentheses: the number of isolates tested (b); the number of
sensitive isolates (c); the number of susceptible-dose-dependent isolates (d);
and the number of resistant isolates (e); Sensitive isolates: MIC ≤ 8.0 μg/mL
for fluconazole (FLU) and ≤ 0.125 μg/mL for itraconazole (ITRA); susceptible-
dose-dependent isolates: MIC between 16.0 and 32.0 μg/ml for FLU, and 0.25
and 0.5 μg/ml for ITRA; resistant isolates: MIC ≥ 64.0 μg/ml for FLU and ≥ 1.0
μg/ml for ITRA.
f Minimum fungicidal concentration - MFC; The MFC50 and
MFC90 are the MFCs capable of inhibiting 50% and 90% of the isolates,
respectively.
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3)
(Figures 1, 2, 3).
In the infection by SCA, the inhibitory activity of FLU
was superior only to that of HE and BUTE at 1% (p <
0.001), which at this concentration showed similar beha-
vior (p > 0.05) and inhibited fungal growth compared to
the negative control, but did not lead to elimination of
the infection. The treatments with 2.5% and 5.0% HE
and BUTE showed similar profiles of inhibition of infec-
tion, comparable to FLU (p > 0.05) (Figure 1).
In the RCA infection, FLU showed better inhibitory
activity than 1% and 2.5% HE (p < 0.001) and 1% BUTE
(p < 0.001). The HE at 1% and 2.5%, and 1.0% BUTE
did not eliminate the infection, showing similar behavior
to that of the untreated control (p > 0.05). For HE, the
5% concentration showed the best inhibitory activity (p
< 0.001), as did the 2.5% and 5.0% concentrations of
BUTE. There was no difference in the action between
these last two concentrations, and also between the HE
and BUTE at the 5% concentration (p > 0.05) (Figure 2).
The RCA was resistant in vitro only to ITRA, and the
positive control of the treatment was carried out with
FLU for all yeasts tested, which although it is also an
azole, showed excellent activity in vivo. No treatment
was carried out with ITRA itself, because no vaginal for-
mulations of this antifungal exist.
For RCG, the inhibitory activity of HE and BUTE at
all concentrations tested was excellent and similar to
that of FLU (p> 0.05). At the 1% concentration of both
extracts, there was a significant decrease in the CFU
count in the first days of infection (p < 0.05), and the
infection was eliminated on day 14 in the experiment
for HE, and on day 21 for BUTE. At 2.5% and 5.0%,
both extracts showed the same activity, with elimination
of the infection on day 5 (p > 0.05); while the FLU treat-
ment eliminated the infection on day 7 (Figure 3). In
general, HE in a concentration of 5% and BUTE in con-
centrations of 2.5% and 5% were capable of eliminating
the infection induced by the different yeasts tested.
0
10
20
30
40
50
60
70
80
90
100
110
01257 1 4 2 1
Days
FLU 1.0 HE 2.5 HE 5.0 HE
1.0 BUTE 2.5 BUTE 5.0 BUTE Water
CFU/mL
 x 10
3
Figure 1 Colony-forming units (CFU/mL) of yeasts in the
vaginal exudate of Wistar rats treated intravaginally with
hydroalcoholic (HE) and butanolic (BUTE) extracts of Sapindus
saponaria at 1.0%, 2.5%, and 5.0%, 100 μg of fluconazole, or
sterile distilled water at 1, 24, and 48 h after induction of the
vaginal infection, followed for up to 21 days. Each curve
represents the mean (± standard deviation) of the CFU of five rats,
in two independent experiments. Experimental vaginal infection by
Candida albicans susceptible to itraconazole and fluconazole (SCA).
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Figure 2 Colony-forming units (CFU/mL) of yeasts in the
vaginal exudate of Wistar rats treated intravaginally with
hydroalcoholic (HE) and butanolic (BUTE) extracts of Sapindus
saponaria at 1.0%, 2.5%, and 5.0%, 100 μg of fluconazole, or
sterile distilled water at 1, 24, and 48 h after induction of the
vaginal infection, followed for up to 21 days. Each curve
represents the mean (± standard deviation) of the CFU of five rats,
in two independent experiments. Experimental vaginal infection by
C. albicans resistant to itraconazole (RCA).
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The percentage of live HeLa cells did not vary between
the controls and tests, and between HeLa cells exposed
to different concentrations of HE and BUTE (p > 0.05).
The mean of live cells in the different HE concentra-
tions was 94.22 ± 0.1555, and in the BUTE concentra-
tions was 94.41 ± 0.1131 (IC 95% = -0.6295 to 0.2575)
(Figure 4).
SEM
The morphology of the vaginal epithelium of the hyper-
estrogenic rats infected by SCA, RCA, and RCG was
indistinguishable upon examination by SEM images. As a
result of this, we selected figures of RCA, which showed
a profile of elimination of infection with slightly higher
concentrations of the extracts than for SCA and RCG.
Figure 5 shows several yeast cells of C. albicans adhered
to the epithelium (A); greater detail of the adhesion of C.
albicans to the anucleate cells of the vaginal epithelium,
characteristic of the state of pseudo-estrus (B); and
epithelium constituted only by anucleate cells, without
yeasts (C), before and after treatment with FLU or with
the extracts of S. saponaria. Thus, the SEM confirmed
the results of the yeast cultures, with respect to the devel-
opment of the experimental infection as well as its post-
treatment elimination in the conditions tested.
Discussion
Phytochemical analyses of some species of the genus
Sapindus have shown that they are rich in triterpenoid
saponins, containing oleanoic acid and hederagenin with
aglycones [4]. The presence of these compounds was
also confirmed in S. saponaria. In general, saponins
have shown antifungal activity against C. glabrata, C.
albicans, Trichosporon beigeli, Penicillum avelaneum,
Pyriculata oryzae, Cryptococcus neoformans, Coccidioidis
immitis, and Saccharomyces cerevisiae, as well as against
the dermatophytes Microsporum canis and Trichophyton
mentagrophytes [16-18]. Hederagenin isolated from the
pericarps of Sapindus mukurossi exhibits potent antifun-
gal activity against Epidermophyton floccosum, Tricho-
phyton mentagrophytes, T. rubrum, Sabouradites canis,
and C. albicans[18].
The constituents previously identified in the HE and
BUTE in S. saponaria and confirmed by us, that is, S1, S2,
and OGASA-01, are very possibly the same substances that
are responsible for its antifungal action. Because of their
antimicrobial activities, the saponins have been the target
of many studies for the purpose of developing phytothera-
peutic options for treatment of infections, that are possibly
less toxic, more efficaceous, and economically accessible
[19-21]. According to Francis et al. [22] the principal
0
10
20
30
40
50
60
70
80
90
100
110
01257 1 4 2 1
Days
FLU 1.0 HE 2.5 HE 5.0 HE
1.0 BUTE 2.5 BUTE 5.0 BUTE Water
CFU/mL
 x 10
3
Figure 3 Colony-forming units (CFU/mL) of yeasts in the
vaginal exudate of Wistar rats treated intravaginally with
hydroalcoholic (HE) and butanolic (BUTE) extracts of Sapindus
saponaria at 1.0%, 2.5%, and 5.0%, 100 μg of fluconazole, or
sterile distilled water at 1, 24, and 48 h after induction of the
vaginal infection, followed for up to 21 days. Each curve
represents the mean (± standard deviation) of the CFU of five rats,
in two independent experiments. Experimental vaginal infection by
C. glabrata resistant to itraconazole and fluconazole (RCG).
Figure 4 Percentage of live HeLa cells after contact with
different concentrations of the hydroalcoholic (HE) and
butanolic (BUTE) extracts from S. saponaria, with no significant
difference between the controls and extracts at all
concentrations tested (p > 0.05). Mean of live cells in the
concentrations of HE = 94.22 ± 0.1555; Mean of live cells in the
concentrations of BUTE = 94.41 ± 0.1131 (IC 95% = -0.6295 to
0.2575).
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their interaction with steroids of the fungal membrane.
This same study mentioned plants containing saponins
with proven antifungal activity, among them Kalopanax
pinctus against C. albicans and Cryptococcus neoformans,
and Aspargus officinalis against different types of fungi.
The in vitro susceptibility tests of the FLU, ITRA, HE,
and BUTE against vaginal yeasts were conducted with
the goal of screening isolates for in vivo activity, to
enable comparisons between the activities in vitro and
in vivo and of the degree of antifungal activity for
extracts. With respect to the in vitro susceptibility test
for antifungal azoles, a few C. abicans were resistant to
I T R A ,b u tn o tt oF L U ,i nc o n c o r d a n c ew i t ho t h e rs t u -
dies that also recently demonstrated resistance to azoles
among vaginal isolates of this yeast [9,14]. Some isolates
of C. glabrata were resistant to ITRA and FLU and also
to both antifungals simultaneously, also in concordance
with studies that demonstrated that vaginal isolates of
non- C. albicans, principally C. glabrata, are less suscep-
tible to azoles than is C. albicans [9,23].
Duarte et al. [24] proposed a classification for the
inhibitory activity of plant extracts based on MIC values,
so that MICs below 500 μg/mL represent strong inhibi-
tion, MICs between 600 and 1500 μg/mL moderate inhi-
bition, and MICs above 1600 μg/mL weak inhibition.
According to this classification and from the values of
MIC50 and MIC90 obtained for the isolates of C. albi-
cans, HE and BUTE demonstrated strong inhibitory
activity, and moderate to strong activity against C. glab-
rata (Table 1). Tsuzuki et al. [5] have also demonstrated
in vitro inhibitory and fungicidal activities of extracts of
S. saponaria against some vaginal isolates of C. albicans
and non- C. albicans. However, the degree of inhibitory
activity was not determined.
In the in vivo tests, FLU and HE in a concentration of
5% and BUTE in concentrations of 2.5% and 5% were
capable of eliminating the infection induced by the dif-
f e r e n ty e a s t st e s t e d( S C A ,R C A ,a n dR C G ) ,i n c l u d i n g
those that were resistant to in vitro tests. These results
for in vitro resistant C. albicans and principally C. glab-
rata are important because there are few treatment
options available for management of patients with VVC
caused by these resistant yeasts [9,14]. The polyene deri-
vatives nystatin and amphotericin B are the only pre-
sently available fungicidal drugs. The use of these
medications is limited, principally because of their toxi-
city, and some isolates with dose-dependent susceptibil-
ity or resistance to these antifungals have been found
[9,14]. Notably, FLU, the antifungal that is most fre-
quently used to treat VVC, is only fungistatic. Therefore,
even though the fungicidal activity (MFC) of the extracts
of S. saponaria is not exceptional, the inhibitory activity
         
         
(A)
(B)
(C)
Figure 5 MEV of the vaginal epithelium of hyperestrogenic
Wistar rats after infection with Candida albicans. In (A) many
yeasts adhered to the epithelium. In (B) larger detail of the adhesion
of C. albicans to the anucleate cells of the vaginal epithelium,
characteristic for the state of pseudo-estrus. In (C) epithelium
composed only of anucleate scales, without yeasts, after treatment
with fluconazole and with the extracts from S. saponaria.
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experiments did not use a previously purified antifungal
substance, which would be necessary for more definite
conclusions about antifungal activity.
Furthermore, it must be considered that C. glabrata is
the second most frequently isolated species in cases of
VVC, preceded only by C. albicans; and that in some
human populations the rate of isolation of non- C. albi-
cans yeasts has increased [25,26], emphasizing the
importance of the antifungal activity of S. saponaria and
of continuing studies with this plant.
In general, HE in a concentration of 5% and BUTE in
concentrations of 2.5% and 5% were capable of eliminat-
ing the infection induced by the different yeasts tested.
The results also evidenced the importance of correct
identification of the yeasts in cases of VVC, as well as
the determination of their in vitro profile of susceptibil-
ity to commercially available antifungals, because there
were clear differences among the different isolates in the
susceptibility profile, both in vitro and in vivo.
The results for cell toxicity indicate an absence of toxi-
city of the extracts to the cervical cells, a positive sign for
the continuity of studies with S. saponaria. However, the
animal toxicity is yet to be determined. Jacobs [27] has
previously demonstrated the absence of cellular toxicity of
S. saponaria. Interestingly, in tumor cells the toxicity
appears to change, since Quetin-Leclerq et al. [28] demon-
strated cytotoxic activity of saponins isolated from certain
plant species, among them S. mukorossi, in B16 melanoma
cells and HeLa human tumor cells, and Meyer et al. [29]
demonstrated cytotoxic activity of the ethanol extract of S.
saponaria on cells from an ascitic tumor.
Conclusions
Our results demonstrated that HE and BUTE from S.
saponaria show inhibitory and fungicidal activity in vitro,
in addition to in vivo activity against azole-resistant vaginal
isolates of C. glabrata and azole-susceptible and resistant
isolates of C. albicans. Also considering the absence of
cytotoxicity and the low concentrations of the extracts
necessary to eliminate the infection in vivo, HE and BUTE
constitute a promising source to continue studies with
purified antifungal substance in VVC yeast isolates. There
is still a need to determine the mechanisms of antifungal
activity in order to validate the use of S. saponaria as an
antifungal phytotherapeutic product.
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